NCT06280209 - A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN 351 in Participants With Duchenne Muscular Dystrophy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 3, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions

Duchenne Muscular Dystrophy

Interventions

DRUG

BMN 351

Anti-sense Oligonucleotide BMN 351 will be administered intravenously.

Trial Locations (7)

RECRUITING

Hospital Viamed Santa Angela De la Cruz, Seville

RECRUITING

Fondazione Serena Onlus - Centro Clinico NeMO Milano, Milan

RECRUITING

UOC Fase I - Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore, Rome

RECRUITING

Yeditepe University Kosuyolu Hospital, Istanbul

RECRUITING

Leids Universitair Medisch Centrum, Leiden

RECRUITING

Hospital Sant Joan de Deu, Barcelona

RECRUITING

Great Ormond Street Hospital NHS Foundation Trust, London